These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 19740401)

  • 1. Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction.
    Strandell J; Bate A; Hägg S; Edwards IR
    Br J Clin Pharmacol; 2009 Sep; 68(3):427-34. PubMed ID: 19740401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system).
    Alsheikh-Ali AA; Karas RH
    Am J Cardiol; 2007 Feb; 99(3):379-81. PubMed ID: 17261402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rhabdomyolysis and statins: A pharmacovigilance comparative study between statins.
    Montastruc JL
    Br J Clin Pharmacol; 2023 Aug; 89(8):2636-2638. PubMed ID: 37186323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis.
    McAdams M; Staffa J; Dal Pan G
    Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):229-39. PubMed ID: 18175291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cataracts and statins. A disproportionality analysis using data from VigiBase.
    Macías Saint-Gerons D; Bosco Cortez F; Jiménez López G; Castro JL; Tabarés-Seisdedos R
    Regul Toxicol Pharmacol; 2019 Dec; 109():104509. PubMed ID: 31669197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class.
    Hoffman KB; Kraus C; Dimbil M; Golomb BA
    PLoS One; 2012; 7(8):e42866. PubMed ID: 22936996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors.
    Rowan C; Brinker AD; Nourjah P; Chang J; Mosholder A; Barrett JS; Avigan M
    Pharmacoepidemiol Drug Saf; 2009 Apr; 18(4):301-9. PubMed ID: 19206087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase.
    Edwards IR; Star K; Kiuru A
    Drug Saf; 2007; 30(6):515-25. PubMed ID: 17536877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for rhabdomyolysis with simvastatin and atorvastatin.
    Ronaldson KJ; O'Shea JM; Boyd IW
    Drug Saf; 2006; 29(11):1061-7. PubMed ID: 17061911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statin-associated immune-mediated necrotizing myopathy: a retrospective analysis of individual case safety reports from VigiBase.
    Essers D; Schäublin M; Kullak-Ublick GA; Weiler S
    Eur J Clin Pharmacol; 2019 Mar; 75(3):409-416. PubMed ID: 30430215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse drug reactions of statins in children and adolescents: a descriptive analysis from VigiBase, the WHO global database of individual case safety reports.
    Conte C; Rousseau V; Vert C; Montastruc F; Montastruc JL; Durrieu G; Olivier P
    Fundam Clin Pharmacol; 2020 Aug; 34(4):518-520. PubMed ID: 32022302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction potential between clarithromycin and individual statins-A systematic review.
    Hougaard Christensen MM; Bruun Haastrup M; Øhlenschlaeger T; Esbech P; Arnspang Pedersen S; Bach Dunvald AC; Bjerregaard Stage T; Pilsgaard Henriksen D; Thestrup Pedersen AJ
    Basic Clin Pharmacol Toxicol; 2020 Apr; 126(4):307-317. PubMed ID: 31628882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statins and immune-mediated necrotizing myopathy: Variability in the risk.
    Trenque T; Hadjoudj J; Trenque A; Tralongo F; Martin S; Azzouz B
    Therapie; 2024; 79(3):365-370. PubMed ID: 37625939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological interactions of statins.
    Paoletti R; Corsini A; Bellosta S
    Atheroscler Suppl; 2002 May; 3(1):35-40. PubMed ID: 12044584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statin-related neurocognitive disorder: a real-world pharmacovigilance study based on the FDA adverse event reporting system.
    Xiao M; Li L; Zhu W; Wu F; Wu B
    Expert Rev Clin Pharmacol; 2024 Mar; 17(3):255-261. PubMed ID: 38275183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statins and erectile dysfunction: results of a case/non-case study using the French Pharmacovigilance System Database.
    Do C; Huyghe E; Lapeyre-Mestre M; Montastruc JL; Bagheri H
    Drug Saf; 2009; 32(7):591-7. PubMed ID: 19530745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins).
    Igel M; Sudhop T; von Bergmann K
    Eur J Clin Pharmacol; 2001 Aug; 57(5):357-64. PubMed ID: 11599653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Muscular adverse effects of statins.
    Prescrire Int; 2003 Feb; 12(63):21. PubMed ID: 12602397
    [No Abstract]   [Full Text] [Related]  

  • 20. Statin-induced rhabdomyolysis from azithromycin interaction in a patient with heterozygous SLCO1B1 polymorphism.
    Burns H; Russell L; Cox ZL
    J Clin Pharm Ther; 2021 Jun; 46(3):853-855. PubMed ID: 33277702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.